# Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects

> **NCT06861842** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Centro de Atencion e Investigacion Medica** · enrollment: 24 (estimated)

## Conditions studied

- Healthy
- Healthy Donors

## Interventions

- **DRUG:** Theralite®
- **DRUG:** Actilitio®

## Key facts

- **NCT ID:** NCT06861842
- **Lead sponsor:** Centro de Atencion e Investigacion Medica
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861842, "Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06861842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*